

(51) International Patent Classification:
C07K 14/775 (2006.01)(21) International Application Number:
PCT/US2012/024020(22) International Filing Date:
6 February 2012 (06.02.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/440,371 7 February 2011 (07.02.2011) US
61/452,630 14 March 2011 (14.03.2011) US
61/487,263 17 May 2011 (17.05.2011) US(71) Applicant (for all designated States except US):
CERENIS THERAPEUTICS HOLDING S.A. [FR/FR];
Bât. A, 265 rue de la Découverte, F-31670 Labège (FR).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **ACKERMANN, Rose** [US/US]; 9600 Oak Pointe Lane, Northville, Michigan 48167 (US). **DASSEUX, Jean-Louis** [FR/FR]; Bât. B, 7 Allées Charles Malpel, F-31300 Toulouse (FR).**ONICIU, Daniela Carmen** [FR/FR]; Appt. 302, 18 Rue Sainte Anne, F-31000 Toulouse (FR).(74) Agents: **WAIS, Rebecca J.** et al.; DECHERT LLP, Suite 700, 2440 W. El Camino Real, Mountain View, California 94040-1499 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

[Continued on next page]

(54) Title: LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOF



(57) Abstract: The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods.



LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, **Published:**

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,

GW, ML, MR, NE, SN, TD, TG).

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*